A Phase 3 interventional study of liraglutide and oral anti-diabetic drug in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 36 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-12-18.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 32nd largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 45th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 25–70
Mansa · Sites in United States
Ages 10+
Biolingus · Sites in Hong Kong
Ages 18–65
RenJi Hospital · Sites in China
Ages 18–65
University of Virginia · Sites in United States
Ages 21–60 · Healthy volunteers
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 21 · Phase 3 46 · Phase 4 48
First in 1999; this study’s year is marked. 21 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 363 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 62 across the 151 interventional studies. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 151 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 27 open now, 31 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 149th largest by enrollment of the 430 interventional ones that give a count, is one of 24 that started in 2012, is one of 187 in phase 3, and was the 265th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing liraglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03883412University of VirginiaEffect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007) | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, from their registry updates:
Among Novo Nordisk A/S’s 645 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial was conducted in Japan. The aim of this trial was to evaluate the safety and efficacy of once daily administration of liraglutide in combination with an oral anti-diabetic drug (OAD) in Japanese subjects with type 2 diabetes who are insufficiently controlled on OAD monotherapy. All subjects will continue their pre-trial OAD (either glinide, metformin, alpha-glucosidase inhibitor or thiazolidinedione) during the trial at unchanged type and dose.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's enrollment of 363 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: liraglutide
Drug: oral anti-diabetic drug
0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
Incidence of Treatment Emergent Adverse Events (AEs)
Adverse events were defined as events occurring after administration of trial product and no later than 7 days after last day of treatment. Severe AEs: considerable interference with subject's daily activities. Moderate AEs: Marked symptoms, moderate interference with the subject's daily activities. Mild AEs: No or transient symptoms, no interference with the subject's daily activities. Serious AEs: AEs that resulted in any of the following: death, a life-threatening experience, hospitalization/prolongation of existing hospitalization, persistent/significant disability, and congenital anomaly.
Time frame: Week 0 to Week 52 + 7 days
Number of Confirmed Hypoglycaemic Episodes
Confirmed hypoglycaemic episodes consisted of the pool of episodes of severe hypoglycaemia as well as minor hypoglycaemic episodes \[An episode with symptoms consistent with hypoglycaemia with confirmation by plasma glucose \<3.1 mmol/L (56 mg/dL) or full blood glucose \<2.8 mmol/L (50 mg/dL) and which is handled by the subject himself or herself or any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or full blood glucose value \<2.8 mmol/L (50 mg/dL)\] with a confirmed plasma glucose value of less than 3.1 mmol/L (56 mg/dL).
Time frame: Week 0 to Week 52
Change in HbA1c From Baseline to Week 52
Estimated mean change in HbA1c from baseline after 52 Weeks of treatment
Time frame: Week 0, week 52
Change in FPG From Baseline to Week 52
Estimated mean change from baseline in FPG after 52 Weeks of treatment
Time frame: Week 0, week 52
The trial was conducted at 36 sites in Japan.
| Milestone | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| Started | 243 | 120 |
| Exposed | 240 | 120 |
| Completed | 221 | 111 |
| Not completed | 22 | 9 |
| Withdrew: Adverse event | 9 | 4 |
| Withdrew: Protocol violation | 1 | 2 |
| Withdrew: Withdrawal criteria | 1 | 0 |
| Withdrew: Unclassified | 11 | 3 |
Adverse events were defined as events occurring after administration of trial product and no later than 7 days after last day of treatment. Severe AEs: considerable interference with subject's daily activities. Moderate AEs: Marked symptoms, moderate interference with the subject's daily activities. Mild AEs: No or transient symptoms, no interference with the subject's daily activities. Serious AEs: AEs that resulted in any of the following: death, a life-threatening experience, hospitalization/prolongation of existing hospitalization, persistent/significant disability, and congenital anomaly.
| Events/100 years of patient exposure | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| All AEs | 361 | 331 |
| Mild AEs | 345 | 321 |
| Moderate AEs | 14 | 9 |
| Severe AEs | 2 | 2 |
| Serious AEs | 5 | 9 |
Confirmed hypoglycaemic episodes consisted of the pool of episodes of severe hypoglycaemia as well as minor hypoglycaemic episodes \[An episode with symptoms consistent with hypoglycaemia with confirmation by plasma glucose \<3.1 mmol/L (56 mg/dL) or full blood glucose \<2.8 mmol/L (50 mg/dL) and which is handled by the subject himself or herself or any asymptomatic PG value \<3.1 mmol/L (56 mg/dL) or full blood glucose value \<2.8 mmol/L (50 mg/dL)\] with a confirmed plasma glucose value of less than 3.1 mmol/L (56 mg/dL).
| episodes | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| Number of Confirmed Hypoglycaemic Episodes | 7 | 2 |
Estimated mean change in HbA1c from baseline after 52 Weeks of treatment
| percentage of glycosylated haemoglobin | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| Change in HbA1c From Baseline to Week 52 | -1.21 ± 0.05 | -0.94 ± 0.07 |
Estimated mean change from baseline in FPG after 52 Weeks of treatment
| mmol/L | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| Change in FPG From Baseline to Week 52 | -1.55 ± 0.09 | -1.24 ± 0.12 |
Collected over Adverse events were captured from the time of consent until 52 weeks of treatment and if needed were followed up after the final visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Liraglutide 0.9 mg/Day | — | 11/240 (4.6%) | 161/240 (67.1%) |
| Additional OAD | — | 10/120 (8.3%) | 77/120 (64.2%) |
| Event | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| Deafness neurosensoryEar and labyrinth disorders | 0/240 | 1/120 |
| Chest painGeneral disorders | 0/240 | 1/120 |
| Meningitis herpesInfections and infestations | 0/240 | 1/120 |
| Foot fractureInjury, poisoning and procedural complications | 0/240 | 1/120 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/240 | 1/120 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/240 | 1/120 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/240 | 1/120 |
| Gastric cancer stage IINeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/240 | 1/120 |
| Large intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/240 | 1/120 |
| Limb operationSurgical and medical procedures | 0/240 | 1/120 |
| Event | Liraglutide 0.9 mg/Day | Additional OAD |
|---|---|---|
| NasopharyngitisInfections and infestations | 89/240 | 47/120 |
| ConstipationGastrointestinal disorders | 44/240 | 12/120 |
| Diabetic retinopathyEye disorders | 21/240 | 16/120 |
| NauseaGastrointestinal disorders | 31/240 | 4/120 |
| DiarrhoeaGastrointestinal disorders | 20/240 | 9/120 |
| Abdominal discomfortGastrointestinal disorders | 19/240 | 1/120 |
| CataractEye disorders | 8/240 | 8/120 |
| Back painMusculoskeletal and connective tissue disorders | 13/240 | 3/120 |
| Dental cariesGastrointestinal disorders | 7/240 | 6/120 |
| InfluenzaInfections and infestations | 8/240 | 6/120 |
| Age, Continuous(years) | Liraglutide 0.9 mg/Day | Additional OAD | Total |
|---|---|---|---|
| Mean | 59.6 ± 11.6 | 59.2 ± 10.2 | 59.5 ± 11.1 |
| Sex: Female, Male(Participants) | Liraglutide 0.9 mg/Day | Additional OAD | Total |
|---|---|---|---|
| Female | 58 | 40 | 98 |
| Male | 182 | 80 | 262 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | Liraglutide 0.9 mg/Day | Additional OAD | Total |
|---|---|---|---|
| Mean | 8.1 ± 0.8 | 8.1 ± 0.8 | 8.1 ± 0.8 |
| Fasting plasma glucose (FPG)(mmol/L) | Liraglutide 0.9 mg/Day | Additional OAD | Total |
|---|---|---|---|
| Mean | 8.68 ± 1.61 | 8.96 ± 1.82 | 8.77 ± 1.69 |
Ran from Jan 2012 to primary completion in Apr 2013, 15 months.
Results were first posted in May 2014, 1 year 1 month after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide